TP 0413Alternative Names: TP-0413
Latest Information Update: 31 Jan 2017
At a glance
- Originator Tolero Pharmaceuticals
- Mechanism of Action Bone morphogenetic protein modulators; Hepcidin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anaemia
Most Recent Events
- 26 Jan 2017 Tolero Pharmaceuticals has been acquired by Sumitomo Dainippon Pharma
- 07 Aug 2014 Preclinical trials in Anaemia in USA (Parenteral)